Full-Time
VP Financial Analytics & Modeling Leader
Brown & Brown Insurance
5,001-10,000 employees
Provides risk management and insurance solutions
Compensation Overview
$200k - $275k/yr
Remote in USA
Remote
Bachelor's, Master's, MBA
 Consulting |
|---|
Get referred to Brown & Brown Insurance
See people who can refer or advise you
- A bachelor's degree in finance, economics, actuarial science, or a related analytical discipline is required.
- An actuarial designation such as ASA, FSA, or MAAA, or equivalent experience developing actuarial-based forecasting methodologies within healthcare, pharmacy benefits, or related industries, is required.
- At least 10 years of experience in pharmacy benefit consulting, PBM financial analysis, or related healthcare financial strategy roles is required.
- Deep expertise in PBM financial models, pricing structures, contract terms, and industry trends is required.
- Strong actuarial and forecasting acumen, including experience developing utilization, cost, rebate, and specialty trend assumptions for healthcare or pharmacy financial models, is required.
- Experience designing or evolving proprietary analytics platforms is required.
- Knowledge of emerging pharmacy benefit trends, including specialty drug management, biosimilars, and alternative funding programs, is required.
- Proven experience leading and developing high-performing analytics or consulting teams is required.
- Strong strategic thinking skills and the ability to translate complex market dynamics into actionable business direction are required.
- Advanced technical proficiency in Excel and financial modeling, with familiarity with data visualization tools such as Tableau and Power BI, is required.
- Experience working with large datasets, pharmacy and medical claims data, and relational databases is required.
- Define and drive the financial analytics strategy across the national pharmacy consulting practice.
- Lead and develop the national financial analytics team, including mentoring, structuring, and scaling talent to support growth and innovation.
- Define the evolution of financial models and tools in alignment with emerging PBM pricing structures, including transparent or pass-through models, alternative rebate structures, and value-based arrangements.
- Drive innovation in financial analytics by identifying opportunities to enhance proprietary tools for improved insights, automation, and scalability.
- Serve as a senior subject matter expert on PBM financial structures, contract terms, and pricing mechanics in support of complex client engagements and negotiations.
- Partner cross-functionally with divisional leadership, client engagement, and product teams to advance integrated solutions and operational efficiencies.
- Provide strategic oversight of financial deliverables, ensuring consistency, accuracy, and high-quality outputs across client work.
- Guide complex financial analyses tied to PBM contracts, pricing guarantees, rebate structures, and total cost of care evaluation.
- Influence thought leadership and market positioning through internal strategy discussions and external-facing insights on pharmacy benefit trends.
- Drive process standardization and scalability by improving workflow, governance, and quality assurance across financial analytics operations.
- Own the development and governance of pharmacy trend assumptions and actuarial forecasting methodologies, ensuring models reflect utilization changes, inflationary pressures, specialty drug pipeline impacts, biosimilar adoption, and evolving PBM contracting structures.
- A master's degree or MBA is preferred.
- An actuarial designation such as ASA, FSA, or MAAA is preferred.
Brown & Brown provides risk management and insurance solutions to businesses and individuals through its Retail and Specialty Distribution segments. The company works by acting as an intermediary to identify specific risks and connect customers with tailored insurance policies that protect their assets. Unlike many competitors, it combines the scale of a large global brokerage with a decentralized culture that emphasizes local community involvement and a team-based approach to service. Its goal is to provide superior risk protection and long-term security for customers by consistently prioritizing their best interests.
Company Size
5,001-10,000
Company Stage
IPO
Headquarters
Leeds, United Kingdom
Founded
1914
Get referred to Brown & Brown Insurance
See people who can refer or advise you
Simplify's Take
What believers are saying
- Accession synergies remain $30 million to $40 million for 2026.
- Q2 2026 revenue surged 30.4% to $1.68 billion, driven by contingents.
- July 22, 2026 AI partnerships target faster sales cycles and stronger margins.
What critics are saying
- Morgan Stanley cut Brown & Brown to Underweight on July 6, 2026.
- Organic revenue fell 0.7% in Q2 2026, exposing acquisition dependence.
- Florida property sensitivity and middle-market competition pressure margins, growth, and talent retention.
What makes Brown & Brown Insurance unique
- Brown & Brown combines national brokerage scale with 44 states and 14 countries.
- Its acquisition machine delivered Accession and $410 million Q2 2026 revenue.
- Management embeds Anthropic, McKinsey, and Accenture across workflows for AI productivity gains.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Student Loan Assistance
Tuition Reimbursement
Mental Health Support
Unlimited Paid Time Off
Paid Vacation
Paid Holidays
Company News
Brown & Brown shares are trading at a discount to the insurance brokerage industry, with a forward price-to-earnings ratio of 15.04X versus the industry average of 16.51X. The company has a market capitalisation of $23.96 billion. The stock has gained 27.4% over the past three months, outperforming the industry's 22.4% growth. Analysts' average price target of $76.44 suggests a potential 7.6% upside from recent levels. The Zacks Consensus Estimate projects 2026 earnings per share to increase 5.6% year-over-year, with revenues reaching $7.04 billion, up 19.2%. Growth is supported by increasing new business, strong client retention, and strategic acquisitions. The company's recent Accession acquisition contributed approximately $410 million to second-quarter 2026 revenues, with expected synergies of $30-$40 million in 2026.
Five insurance brokers stocks reported largely satisfactory Q2 earnings, with revenues beating analyst consensus estimates by 0.8% overall. Share prices have held steady, rising 2.1% on average since results were released. Brown & Brown reported revenues of $1.68 billion, up 30.4% year on year. However, this figure fell short of analyst expectations by 2.5%. Despite scoring the fastest revenue growth amongst peers, it had the weakest performance against analyst estimates. The stock has risen 2.7% since reporting and currently trades at $71.60. Ryan Specialty delivered the strongest Q2 performance, reporting revenues of $916.6 million, up 7.2% year on year and outperforming analyst expectations by 5.3%. The insurance brokerage industry benefits from rising risk complexity and regulatory scrutiny, though faces challenges from labour intensity and wage inflation.
Brown & Brown reported second quarter 2026 results that missed revenue expectations but showed strong year-on-year growth. Revenue rose 30.4% to $1.68 billion, below the $1.72 billion analyst estimate. Management attributed performance to strong contingent commissions, effective acquisition integration, and improved sales processes. CEO J. Powell Brown said the company's enhanced sales model is building momentum with aligned teams generating new business wins. Operating margin declined year-over-year to 22.9% from 24.2%, though the company made progress controlling expenses. Adjusted EBITDA of $611 million beat analyst estimates of $603.1 million. During the earnings call, analysts questioned MGA competition impacts, European expansion plans, and technology investment costs. Management stressed disciplined underwriting and confirmed synergy targets remain unchanged.
Brown & Brown reported Q2 2026 results with revenue of $1.676 billion and net income of $288 million. The insurance broker's shares closed at $70.40, posting a 22.16% gain over 90 days but down 9.30% year-to-date and 23.00% over one year. Valuation models suggest a fair value of $75.63, indicating the stock is 6.9% undervalued. The company's diversified portfolio across geographies and business lines supports earnings stability. However, the price-to-earnings ratio of 19.8x exceeds both the US insurance industry average of 12.1x and the stock's fair ratio of 12.5x. Risks include rising pharmacy costs in benefits and potential Florida legislative changes that could pressure margins.
Brown & Brown shares jumped 5% after reporting second-quarter results. The insurance brokerage firm's revenue grew 30.4% year-over-year to $1.68 billion, slightly below analyst estimates of $1.72 billion. Adjusted earnings per share came in at $1.07, exactly meeting Wall Street expectations. The positive market reaction suggests investors focused on strong top-line growth and profit targets rather than the minor revenue miss. The shares are down 5.9% year-to-date and trading at $73.05, which is 28.8% below their 52-week high of $102.58 from July 2025. Last month, Morgan Stanley downgraded the stock to "Underweight", citing concerns about organic growth reset and a softer pricing cycle.